MARKET

ALNY

ALNY

Alnylam Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

90.85
-1.60
-1.73%
Pre Market: 90.85 0 0.00% 08:00 11/13 EST
OPEN
92.20
PREV CLOSE
92.45
HIGH
93.09
LOW
90.55
VOLUME
429.82K
TURNOVER
--
52 WEEK HIGH
96.08
52 WEEK LOW
60.27
MARKET CAP
10.11B
P/E (TTM)
-11.7106
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALNY and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALNY News

  • Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference
  • Business Wire.16h ago
  • The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict
  • Benzinga.2d ago
  • Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
  • Business Wire.3d ago
  • 4 RNA Therapy Stocks For A Biotech Portfolio
  • Seeking Alpha - Article.5d ago

More

Industry

Biotechnology & Medical Research
+0.28%
Pharmaceuticals & Medical Research
+0.27%

Hot Stocks

Name
Price
%Change

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
More

Webull offers Alnylam Pharmaceuticals, Inc. (ALNY) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.